Digital Turbine rallied on Meta's European plans, says B. Riley » 08:48 APPS, META Digital Turbine, Inc. (APPS) NasdaqCM - NasdaqCM Real Time Price. 9.28+0.67 (+7.78%) At close: June 30 04:00PM EDT 9.32 +0.04 (+0.43%) Pre-Market: 08:55AM EDT
Macau reports June casino revenue up 513.9% to 15.21B patacas 08:43 LVS, MGM, WYNN, MLCO Melco Resorts & Entertainment Limited (MLCO) NasdaqGS - NasdaqGS Real Time Price. 12.21+0.01 (+0.08%) At close: June 30 04:00PM EDT
I know this was a SPAC and those fat cats made out like bandits at Blackrock... but I continue to get the vibe that this name is ready to move- Alight is well positioned to generate solid revenue growth, says DA Davidson » 08:27 ALIT Alight, Inc. (ALIT) NYSE - NYSE Delayed Price. 9.24+0.13 (+1.43%) At close: June 30 04:00PM ED
Worksport opens R&D facility in Springfield, Missouri » 08:07 WKSP Worksport Ltd. (WKSP) NasdaqCM - NasdaqCM Real Time Price. 2.4100-0.0900 (-3.60%) At close: June 30 03:57PM EDT 2.4700 +0.06 (+2.49%)
Ternium remains Morgan Stanley's top pick in Latam M&M sector » 08:01 TX Metals Company announces availability of data from NORI-D exploration area » 07:48 TMC
monday gummy- Genfit S.A. (GNFT) NasdaqGS - NasdaqGS Real Time Price. 3.5400-0.6000 (-14.49%) At close: June 30 04:00PM EDT 3.7500 +0.21 (+5.93%) <--------------- Pre-Market: 09:11AM EDT
Genfit price target raised to $11 from $9 at H.C. Wainwright » 09:12 GNFT Description Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.
CymaBay 'competitive overhang' now removed, says William Blair » 08:12 CBAY, GNFT, IPSEY wow- CymaBay Therapeutics, Inc. (CBAY) NasdaqGS - NasdaqGS Real Time Price. 10.95+3.11 (+39.67%)<--------- Fri At close: June 30 04:00PM EDT
After basically putting this company on the map, now they move on their own- WiMi Hologram is developing a digital twin-based human-robot collab system » 08:02 WIMI
Yea digital twin robot- you heard that right..... flash forward 30 years.... do you go to work today or send your digital twin robot? Can digital twin robots be sexually harassed at the workplace?